Silence brings the noise to Takeda with phase 2 blood cancer win Read more →

Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push Read more →

Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program Read more →